October 28th 2024
The significance of antiretroviral therapy (ART) has been a game changer for people living with HIV (PLWH). Still, there are some cardiovascular risks associated with different ART classes—particularly protease inhibitors (PIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and integrase strand transfer inhibitors (INSTIs). Authors review a piece in the literature around this area of study.
CDC Releases Updated Guidelines on HIV Nonoccupational Post-Exposure Prophylaxis
May 27th 2016The Centers for Disease Control and Prevention (CDC) has released updated guidelines for the use of nonoccupational post-exposure prophylaxis (nPEP) in persons in the United States, after exposure to human immunodeficiency virus (HIV) outside the health care setting.
Read More
Australian Olympics Team to Receive Anti-Zika Condoms for Rio 2016
May 18th 2016On May 16, 2016, the Australian Olympic Committee (AOC) announced that the country’s Olympic team members will receive Dual Protect VivaGel condoms, the world’s only antiviral condom, for the 2016 Olympic Games in Rio de Janeiro.
Read More
HPV-Related Health Problems Linked With Stress and Depression
May 16th 2016A recent study has shown that stress and depression in adolescent females are linked to human papillomavirus (HPV)-related health problems—in particular, whether the viral infection persists long enough to increase the risk of cervical cancer.
Read More
HIV May Cause Premature Aging in Infected Individuals
May 4th 2016The results of a methylome-wide analysis of human immunodeficiency virus (HIV) chronically infected, combination anti-retroviral therapy (cART)-treated individuals recently published in Molecular Cell suggest that HIV+ individuals have an epigenetic age 4.9 years older than healthy controls, resulting in an expected total mortality risk increase of 19%.
Read More
Controversy Arises on Added Benefit of Rilpivirine for HIV-Positive Children and Adolescents
May 2nd 2016In a one-arm study examined by the German Institute for Quality and Efficiency in Health Care (IQWiG), the added benefit of rilpivirine for HIV-positive children and adolescents between the ages of 12 and 18, was not proven, contrary to the belief of the manufacturer.
Read More
Study Shows HIV Can Develop Resistance to Promising HIV Therapy
April 28th 2016A recent study has shown that although the CRISPR/Cas9 gene editing technology can stop human immunodeficiency virus (HIV) replication, it also results in unexpected viral resistance and thereby limits use of the technology in HIV therapy.
Read More
Study Challenges WHO Recommendation to Increase HCV Screening in HIV-Infected Populations
April 27th 2016In a recent study of 1,812 human immunodeficiency virus (HIV)-infected individuals in sub-Saharan Africa, researchers found that none of these individuals had confirmed hepatitis C virus replication.
Read More
Age-related Diseases Don't Occur Earlier in HIV-infected Patients
November 6th 2014Despite previous research suggesting HIV patients have an increased likelihood of suffering from a heart attack, kidney failure, or cancer, Johns Hopkins Bloomberg School of Public Health investigators showed the age they encounter these conditions were similar to their uninfected counterparts.
Read More